IFN-α-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 567-572

  Hiroishi, Kazumasa ^a   Tüting, Thomas ^a,b   Lotze, Michael T ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNOLOGY;

EID: 17544404678     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.567     Document Type: Article

References (28)

1. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc. R. Soc. London Ser. B. 147:258.
2. Belardelli, F. 1995. Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161.
3. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Function role of type I and type II interferons in antiviral defense. Science 264:1918.
4. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947.
5. von Hoegen, P., R. Zawatzky, and V. Schirrmacher. 1990. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/β. Cell. Immunol. 126:80.
6. + T cell-mediated tumor rejection and development of antitumor immunity: comparative studies with IFN-γ-producing TS/A cells. J. Immunol. 153:4604.
7. McRae, B. L., R. Tolouei Semnani, M. P. Hayes, and G. A. van Seventer. 1998. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160:4298.
8. Hiroishi, K., T. Tüting, H. Tahara, and M. T. Lotze. 1999. Interferon-α gene therapy in combination with CD80-transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther. In press.
9. Tan, M. H., E. D. Holyoke, and M. H. Goldrosen. 1976. Murine colon adenocarcinomas: methods for selective culture in vitro. J. Natl. Cancer Inst. 56:871.
10. Gresser, I., M. G. Tovey, M. E. Bandu, C. Maury, and D. Brouty-Boye. 1976. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144:1305.
11. Gresser, I., M. G. Tovey, C. Maury, and M. T. Bandu. 1976. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J. Exp. Med. 144:1316.
12. Reeves, M. E., R. E. Royal, J. S. Lam, S. A. Rosenherg, and P. Hwu. 1996. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672.
13. Tüting, T., A. Gambotto, J. Baar, I. D. Davis, W. J. Storkus, P. J. Zavodny, S. Narula, H. Tahara, P. D. Robbins, and M. T. Lotze. 1997. Interferon-α gene therapy for cancer: retroviral transduction of ribroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther. 4:1053.
14. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392.
15. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
16. Biron, C. A. 1997. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9:24.
17. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521.
18. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
19. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
20. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
21. Chen, L., P. McGowan, S. Ashe, J. Johnson, Y. Li, I. Hellstorm, and K. E. Hellstorm. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
22. Subauste, C. S., R. de Waal Malefyt, and F. Fuh. 1998. Role of CD80 (B7. 1) and CD86 (B7.2) in the immune response to an intracellular pathogen. J. Immunol. 160:1831.
23. Daniel, P. T., A. Kroidl, S. Cayeux, R. Bargou, T. Blankenstein, and B. Dörken. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159:3808.
24. L. Immunity 3:87.
25. Walker, P. R., P. Saas, and P.-Y. Dietrich. 1997. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158:4521.
26. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835.
27. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
28. Colombo, M. P., and G. Forni. 1994. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15:48.